Product
CV2CoV
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 1, Open-label, Safety, Reactogenicity, and Immunogenicity Trial of the CV2CoV mRNA Vaccine Against SARS CoV 2 in Seropositive Adult ParticipantsStatus: Completed, Estimated PCD: 2023-03-07